Budapest XII

• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto … Ended recruitment
  2023-503916-33-00 5 2021-03-24 Diffuse Large B-Cell Lymphoma (DLBCL)
• This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat … Ended recruitment
  2023-507338-26-00 5 2021-02-01 Histologically documented gastric or gastroesophageal junction adenoca
• A clinical study of different treatments for kidney cancer (MK-3475-03B) Ended recruitment
  2023-506839-15-00 9 2020-12-21 Renal cell carcinoma
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended recruitment
  2023-504959-27-00 5 2020-12-09 Participants with Limited Stage-Small Cell Lung Cancer, who have recei
• Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca … Ended recruitment
  2024-516653-44-00 5 2020-11-30 HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
• Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended recruitment
  2023-505852-23-00 5 2020-11-12 High risk recurrent prostate cancer previously treated with radical pr
• A Randomized, Open-label Phase 3 Study of Combination Amivantamab and CarboplatinPemetrexed Therapy, Compared with Carboplatin-Pemetrexed, i … Ended recruitment
  2023-506033-29-00 5 2020-10-09 EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell
• A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed … Ended recruitment
  2022-502746-27-00 5 2020-08-21 Endometrial Cancer
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell … Ended recruitment
  2023-503591-25-00 5 2020-06-09 Non-small cell lung cancer
• Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2 … Ended recruitment
  2023-505042-25-00 5 2020-05-05 Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
• A trial to learn how camizestrant (AZD9833) works compared to fulvestrant and how safe it is in women with advanced breast cancer who have g … Ended recruitment
  2023-504974-40-00 4 2020-04-24 Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap … Ended recruitment
  2022-501531-16-00 5 2020-01-24 esophageal carcinoma
• A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer Ended recruitment
  2023-506551-23-00 5 2019-11-21 Recurrent or primary advanced (Stage III or IV) endometrial cancer
• Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme … Ended recruitment
  2023-508841-42-00 3 2019-10-30 Different types of advanced cancer
• An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu … Ended recruitment
  2023-506184-34-00 5 2019-08-09 Advanced Malignancies
• A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended recruitment
  2023-509576-42-00 5 2019-02-21 Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
• Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended recruitment
  2023-506921-12-00 5 2018-12-27 ER+/HER2- Breast Cancer
• MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable LA HNSCC (Locoregionally Advanced Head and Neck Squamo … Ended recruitment
  2022-500254-41-00 5 2018-12-13 Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamou
• A trial to learn how well durvalumab and chemotherapy with or without tremelimumab work in adults with advanced cancer of the bladder or uri … Ended recruitment
  2024-510976-19-00 5 2018-11-30 Patients with Unresectable Locally Advanced or Metastatic Urothelial C
• LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended recruitment
  2023-507657-15-00 5 2018-09-13 Ulcerative Colitis
• A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Re … Ended recruitment
  2023-506861-76-00 5 2018-08-09 Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplasti

Showing 217–240 of 317 trials